Search This Blog

Wednesday, March 8, 2017

Amgen Presents Overall Survival Data From KYPROLIS® (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop

Amgen - Investors - RSS Content

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.